Eroxon Beats Viagra Hands Down

Beating off and intimate sex has just gotten way easier and faster.

George Schneider

Feb 07, 2025

As promised, Future Medical (FAMDF), the maker of Eroxon, has started its aggressive push into the U.S. market.

Press play on this Youtube video and start playing.

source: Youtube

Futura Medical (FAMDF) makes the only FDA authorized topical cream that allows a man to achieve erection within 10 minutes. Think of that! Instead of having to anticipate and plan an intimate moment 4 hours ahead of time with products of competitors like Viagra or Cialis, this new product allows intimate sex at a whim. Just 10 minutes later a man can achieve erection and engage in solo or intimate sex with his partner. No advance planning necessary.

This is a veritable revolution in medical applications for erectile dysfunction.

Psychological Benefits

From a psychological viewpoint, users benefit from increased confidence, lesser fears of performance anxiety, heightened sexual satisfaction and overall knowledge that future sexual encounters will be productive and meaningful.

Futura has been distributing this product in the U.K., the European Union, Latin America and Asia for over several years now and sales have been increasing steadily as uptake from ads and word of mouth has contributed to the accepted use of this product. It is truly a game changer.

And today their product can be found in stores everywhere, including Target, CVS, Walgreens and Walmart, to name a few.

Source: all pictures in this article are sourced from Target.com web site

A few days ago, the company reported good sales, but the CEO acknowledge he was hoping for better numbers. He also guided sales and revenue lower for 2025 based upon these slower numbers, however he was encouraged that sales would pick up in 2026 and beyond.

Because of the disappointment in sales figures in the company’s latest report, the stock price fell to just $.20 per share.

Source: Yahoo Finance

This fall in price may be regarded as an opportunity for new investors to make an initial investment, or for earlier investors to average down their previous price paid for this stock.

Female Sexual Dysfunction, China, Next On The Agenda For Eroxon Creator Futura

Drug-free erectile dysfunction “stimgel” creator Futura wants to see if the technology underpinning Eroxon can be applied to female sexual dysfunction. Breaking into China is also high up on the agenda for the UK-based R&D company’s CEO James Barder, he reveals in this exclusive interview.

Source:Insights.citeline.com

“Futura Medical PLC (AIM:FUM, OTC:FAMDF) says its 2024 revenue and profit were ahead of market expectations, driven by the strong launch of its erectile dysfunction gel, Eroxon.

Sales reached at least £13.7million, up from £3.1 million in 2023. The product is now sold in 15 countries, including the US, with plans to expand to 20 by the end of 2025.
Eroxon launched in the US in October 2024 through Futura’s partner Haleon, triggering a $5 million milestone payment. Initial sales have been positive, but consumer uptake has been slower than expected.”
“Despite strong early demand, Futura has lowered its 2025 outlook. It now expects revenue to be 50% below previous forecasts, meaning it is unlikely to achieve the threshold for receiving sales-based milestone payments in 2025. The company anticipates a loss instead of a profit for the current year.

“Whilst it has been slower than anticipated to generate consumer awareness, and resulting sales, in a completely new product in a new consumer market that naturally has some stigma attached to it, we, and our partners, remain confident in the future prospects for Eroxon,” said CEO James Barder.

“Our commercial partners are committed to building the Eroxon brand based upon the learnings gleaned post-launch, especially within the key US market, as we look to meet the unmet demand for a product of this nature and take advantage of the opportunities available to us.”

Futura is also expanding its product range. It is developing Eroxon Intense, aimed at users seeking stronger effects, and WSD4000, a topical gel for female sexual dysfunction. Both products have shown positive results in trials.”

Source: Proactive investors

Your Takeaway

Investors well-remember what a blockbuster Viagra was. It also took some time before consumer uptake eventually exploded. I believe this product will eventually reach huge sales and earnings for Futura and could easily pose a future threat to the makers of Viagra and other pill-like medicines in the erectile dysfunction category. Eroxon may at first just nip at the heels of its competitors but may eventually eat their lunches as consumers begin to realize the superior attributes and immediacy that Eroxon affords.

Milk Much More Cash From Your Portfolio with This Strategy
Looking for a conservative way to milk extra money from your stocks?medium.datadriveninvestor.com

Turn $20,000 in Savings into $1000 a Month in Passive Income
It’s easier than you might think to generate $1,000 a month from just $20,000.medium.com

Get Rich as Your Portfolio Collapses
Losing money is the quickest way to earn riches.medium.com

President Musk: “Take Two Horse Pills with Bleach and Don’t Call Me in the Morning”
King Donald sticking his head in the sand; it’s what got us into this mess in the first place.medium.com

Best,

George Schneider, M.A.

Founder and publisher

Retirement: One Dividend At A Time

Disclaimer: This article is intended to provide information to interested parties. As I have no knowledge of individual investor circumstances, goals, and/or portfolio concentration or diversification, readers are expected to complete their own due diligence before purchasing any stocks mentioned or recommended.

Disclosure: I am long all RODAT Portfolio names. The Portfolio continues to build dividend income with reliable, dependable equities which have long histories of increasing the dividend.

Retirement: One Dividend at a Time

Discussion about this post